Westlake Village, Ca., USA - November 9, 2009, Westlake Village, Ca., USA - First California Financial Group announced the appointment of Sung Won Sohn to its board of directors, effective immediately.
Article continues below
Dr. Sohn is widely recognized for his past role as Executive Vice President and Chief Economic Officer for Wells Fargo Banks. He has received many honors for the accuracy of his economic forecasting. In 2006, The Wall Street Journal noted Dr. Sohn as the "most accurate economist in the United States." In 2002, he was named to Time Magazine's Board of Economists, and in 2001, Bloomberg News identified him as "one of the five most accurate forecasters." Dr. Sohn served as a senior economist on the President's Council of Economic Advisors during the Nixon administration, where he was responsible for economic and legislative matters pertaining to the Federal Reserve and financial markets.
Currently, Dr. Sohn is Martin V. Smith Professor at California State University, Channel Islands. Dr. Sohn also serves as Vice Chairman of the board at Forever 21, a leading, multi-national apparel retailer, and sits on the board of directors for Claremont Graduate University and the Music Center in Los Angeles.
Previously, Dr. Sohn was President and Chief Executive Officer of Hanmi Financial Corporation from 2005 through 2007. He joined Norwest Bank Minneapolis in 1974 and held various positions of increasing responsibility focusing on macro-economic forecasting, monetary policy, asset-liability management and regulatory matters in relation to financial institutions. Dr. Sohn was later named senior vice president at the parent company, Norwest Corporation. After the acquisition of Wells Fargo by Norwest Corporation, Dr. Sohn was appointed Chief Economic Officer of the combined entity now known as Wells Fargo & Company. ■
Roche announced that the United States Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours.